Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC

• Published in: JTO clinical and research reports Vol. 3; no. 9; p. 100386
• Main Authors: Schwartzberg, Lee S., Li, Gerald, Tolba, Khaled, Bourla, Ariel B., Schulze, Katja, Gadgil, Rujuta, Fine, Alexander, Lofgren, Katherine T., Graf, Ryon P., Oxnard, Geoffrey R., Daniel, Davey
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.09.2022; Elsevier
• Subjects: Biomarkers; Comprehensive genomic profiling; Liquid biopsy; NSCLC; Original; Tissue-based testing; Comprehensive genomic profiling; Biomarkers; Liquid biopsy; Tissue-based testing; NSCLC
• ISSN: 2666-3643; 2666-3643
• DOI: 10.1016/j.jtocrr.2022.100386

Whereas tumor biopsy is the reference standard for genomic profiling of advanced NSCLC, there are now multiple assays approved by the Food and Drug Administration for liquid biopsy testing of circulating tumor DNA. Here, we study the incremental value that liquid biopsy comprehensive genomic profiling (CGP) adds to tissue molecular testing. Patients with metastatic NSCLC were enrolled in a prospective diagnostic study to receive circulating tumor DNA CGP; tissue CGP was optional in addition to their standard tissue testing. Focusing on nine genes listed per the National Comprehensive Cancer Network (NCCN) guidelines, liquid CGP was compared with available tissue testing results across three subcohorts: tissue CGP, standard-of-care testing of up to five biomarkers, or no tissue testing. A total of 515 patients with advanced nonsquamous NSCLC received liquid CGP. Among 131 with tissue CGP results, NCCN biomarkers were detected in 86 (66%) with tissue CGP and 56 (43%) with liquid CGP (p < 0.001). Adding liquid CGP to tissue CGP detected no additional patients with NCCN biomarkers, whereas tissue CGP detected NCCN biomarkers in 30 patients (23%) missed by liquid CGP. Studying 264 patients receiving tissue testing of up to five genes, 102 (39%) had NCCN biomarkers detected in tissue, with an additional 48 (18%) detected using liquid CGP, including 18 with RET, MET, or ERBB2 drivers not studied in tissue. For the detection of patients with advanced nonsquamous NSCLC harboring 9 NCCN biomarkers, liquid CGP increases detection in patients with limited tissue results, but does not increase detection in patients with tissue CGP results available. In contrast, tissue CGP can add meaningfully to liquid CGP for detection of NCCN biomarkers and should be considered as a follow-up when an oncogenic driver is not identified by liquid biopsy.